.png){kind=icon}
.png){kind=icon}
Return
Multipurposing CARs: Same engine, different vehicles
.png){kind=icon}
OA
AI
DOI：10.1016/j.ymthe.2022.02.012.png)
.png){kind=icon}
.png){kind=icon}
Share.png){kind=icon}
Save
Abstract
En 中文
T cells genetically engineered to recognize and eliminate tumor cells through synthetic chimeric antigen receptors (CARs) have demonstrated remarkable clinical efficacy against B cell leukemia over the past decade. This therapy is a form of highly personalized medicine that involves genetically modifying a patient's T cells to recognize and kill cancer cells. With the FDA approval of 5 CAR T cell products, this approach has been validated as a powerful new drug in the therapeutic armamentarium against cancer. Researchers are now studying how to expand this technology beyond its use in conventional polyclonal ab T cells to address limitations to the current therapy in cancer and applications beyond it. Considering the specific characteristics of immune cell from diverse lineages, several preclinical and clinical studies are under way to assess the advantages of CAR-redirected function in these cells and apply the lessons learned from CAR T cell therapy in cancer to other diseases.
Keywords:
CHIMERIC ANTIGEN RECEPTOR
MESENCHYMAL STEM-CELLS
NATURAL-KILLER-CELLS
REGULATORY T-CELLS
IN-VIVO
NK CELLS
STROMAL CELLS
BONE-MARROW
MONOCLONAL-ANTIBODY
MONOLAYER-CULTURES
AI Summary
Key information extracted from the uploaded paper, including a brief overview, abstract, background, key highlights, visual analysis, and future outlook.
Journal
IF:
12
Papers:
9.9K
Citations:
3.0W
Organization
View more organizations